Pharmastrategyblog - pharmastrategyblog.com - Pharma Strategy Blog
General Information:
Latest News:
Transformative antibody technology in cancer research 30 Jul 2013 | 04:36 pm
Recently, I came across an exciting new development in a Nature publication and couldn’t resist teasing my Twitter followers with…
Update on iNHL and CLL – idelalisib, obinutuzumab and ibrutinib 26 Jul 2013 | 10:24 pm
Yesterday, Gilead announced on their 2Q Earnings Call that they plan to file their PI3K delta inhibitor, idelalisib (formerly CAL-101),…
Exciting times in CLL: an ASCO 2013 interview with Dr Susan O’Brien 11 Jun 2013 | 12:14 am
At the recent ASCO 2013 meeting in Chicago, I had the great pleasure to interview Susan M. O’Brien, MD who…
Exciting times in CLL: an ASCO 2013 interview with Dr Susan O’Brien 11 Jun 2013 | 12:14 am
At the recent ASCO 2013 meeting in Chicago, I had the great pleasure to interview Susan M. O’Brien, MD who…
ASCO 2013 Highlights Part 2 28 May 2013 | 07:42 pm
It’s that time of the year when the annual meeting of the American Society of Clinical Oncology (ASCO) hurtles around…
ASCO 2013 Highlights Part 2 28 May 2013 | 07:42 pm
It’s that time of the year when the annual meeting of the American Society of Clinical Oncology (ASCO) hurtles around…
ASCO 2013 Highlights PD-1 and PD-L1 immunotherapy 16 May 2013 | 11:30 pm
One of the hot topics at this year’s annual ASCO meeting is clearly going to be PD-1 and PD-L1 immunotherapies,…
ASCO 2013 Highlights PD-1 and PD-L1 immunotherapy 16 May 2013 | 11:30 pm
One of the hot topics at this year’s annual ASCO meeting is clearly going to be PD-1 and PD-L1 immunotherapies,…
Reflections of a Medical Oncologist on AACR 2013 22 Apr 2013 | 07:10 pm
Continuing my series of posts about the 2013 annual meeting of the American Association for Cancer Research (AACR), I am delighted…
Reflections of a Medical Oncologist on AACR 2013 22 Apr 2013 | 07:10 pm
Continuing my series of posts about the 2013 annual meeting of the American Association for Cancer Research (AACR), I am delighted…
